Fresh Recalls

Dopamine HCl Inj: recall status

Notice names this product. Pfizer’s Dopamine HCl Inj is named in FDA Class II recall D-0853-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: Lack of Assurance of Sterility Identifying details: Lot # NL5230, Exp Date:10/2027. Units affected: N/A. Status: Ongoing.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Dopamine HCl Inj
Company / brand
Pfizer
Lot / serial / date codes
Lot # NL5230, Exp Date:10/2027
Distribution
US Nationwide.
Agency product description and boundaries

Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

Brand
Pfizer

Recalls naming this model

FDA Class II · Drug · September 23, 2026

Dopamine HCl Inj recall — Pfizer

Lack of Assurance of Sterility

Company / brand: Pfizer recalls

Affected product: Dopamine HCl Inj recall status

Official ID D-0853-2026 · Official record ↗

See all Pfizer recalls →

Verify with the official sources:

Found something wrong or missing? Report a data error.

Compiled from connected official public-domain government data. Sources last checked October 22, 2026 at 12:00 PM UTC.